Key result
Recent management era linked to ~11% higher 3-year survival in not-operated CTEPH.
Why the study?
Treatment options for inoperable CTEPH have evolved with the availability of balloon pulmonary angioplasty and pulmonary vasodilators, prompting analysis of prognostic variables associated with long-term outcome.
Does the recent management era, including the availability of balloon pulmonary angioplasty, improve survival in patients with not-operated chronic thromboembolic pulmonary hypertension compared to the early management era?
Cohort (n=343)
No
Does the recent management era, including the availability of balloon pulmonary angioplasty, improve survival in patients with not-operated chronic thromboembolic pulmonary hypertension compared to the early management era?
Survival of patients with inoperable chronic thromboembolic pulmonary hypertension has significantly improved in the recent era, with balloon pulmonary angioplasty being an independent predictor of improved survival.
Answers are grounded in this paper and cite their sources.
Recent-era survival gains in inoperable CTEPH may support BPA consideration; observational data leaves causal effects open for randomized trials.
BACKGROUND: Treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) have recently evolved with the availability of balloon pulmonary angioplasty (BPA) and pulmonary vasodilators. Our aim was to analyze the prognostic variables associated with long-term outcome in a cohort of patients with not-operated CTEPH. METHODS: From January 2006 to December 2016, 343 newly diagnosed consecutive patients with not-operated CTEPH were diagnosed and followed up in the French Reference Center for Pulmonary Hypertension. Overall long-term survival and prognostic factors according to the diagnosis period (early period, 2006-2012, vs recent period, since 2013, i.e., one year before availability of BPA) were analyzed. RESULTS: In the overall population, baseline New York Heart Association functional class, right atrial pressure, 6-minute walk distance (6MWD), and diagnosis period were independent predictors of survival. The 1- and 3-year survival rates of patients diagnosed in the recent period (n = 170) were 91.6% and 85.0%, compared with 89.0% and 74.3% in patients diagnosed in the early period (n = 173), respectively (p = 0.030). Multivariate analysis from patients diagnosed in the recent period found that baseline 6MWD (per 20 m increase in distance) (hazard ratio [HR], 0.879; 95% confidence interval [CI], 0.832-0.928, p < 0.001) and BPA (HR, 0.307; 95% CI, 0.099-0.957; p = 0.042) were independently associated with survival. CONCLUSIONS: Survival of not-operated patients with CTEPH has significantly improved in the recent management era. New treatment options, including BPA, might have the potential to improve the prognosis of patients with inoperable CTEPH.
No takes yet. Share an insight, caveat, or question.
Taniguchi et al. (2019) conducted a cohort in not-operated chronic thromboembolic pulmonary hypertension (n=343). Recent diagnosis period (since 2013) vs. Early diagnosis period (2006-2012) was evaluated on 3-year survival (p=0.030). Diagnosis in the recent era (since 2013) was associated with improved 3-year survival compared to the early era in patients with not-operated CTEPH.
Synapse has enriched 10 related papers. Consider them for comparative context: